Hispanics in Treatment: The Amoxapine Experience

  • Madeline Gomez
  • Evaristo Gomez


“Amoxapine” (Asendin)(R) is a new antidepressant belonging to the so-called “second generation” of antidepressant drugs. Soon after it was introduced in the U.S.A. Pharmacopoeia and clinical use it was labeled and characterized as an excellent antidepressant with rapidity of action, fewer side effects and effectiveness. 1,2 Later another antidepressant “Trazodone” from the “second generation was introduced with excellent results.3,4 The authors thereafter evaluated in double blind studies both drugs in comparison with Amitriptyline, in Hispanic patients only, Study I, and compared the efficacy of Amoxapine vs. Placebo in Anglosaxons and Hispanic patients, Study II.


Hispanic Patient Illness Duration Antidepressant Efficacy Clinical Global Impression Scale Dysthymic Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ayd, Frank, Jr., Amoxapine: A New Tricyclic Antidepressant. Int. Drug Ther. Newslet., July 1980.Google Scholar
  2. 2.
    Donlon, Patrick T., Amoxapine, A Newly Marketed Tricyclic Antidepressant. Psychiat. Annls., Nov. 1981, 11:11, 379–383.Google Scholar
  3. 3.
    Feighner, J.P., “Trazodone, A Triazolopyridine Derivative in Primary Depressive Disorder,” J. Clin. Psychiat. Vol. 41, No. 7 pp. 350–255, July 1980.Google Scholar
  4. 4.
    Goldberg, Hal, “Treatment of Neurotic Depression with a New Antidepressant,” J. Clin. Psych Pharm., Vol. 1, No. 6, Sup.1981.Google Scholar
  5. 5.
    Wilson, Yan & Hoosen, Peter, A double blind clinical comparison of Amoxapine, Imipramine, -nd Placebo in the treatment of depression. Curr. Ther. Res., Vol. 22, No. 5, Nov. 1977.Google Scholar
  6. 6.
    Data on file “Lederle Laboratores, Wayne, N.J.”Google Scholar
  7. 7.
    Lin, K. M., Finder, E., “Neuroleptic Dosage for Asians,” AM.J.P., 140:4, pp. 490–491, Apr. 1983.Google Scholar
  8. 8.
    Gomez, E., “Loxapine vs. Chlorpromazine in Psychotic Patients.” Grand Rounds G. London Mem. Hosp., Chicago, IL, June 1976.Google Scholar
  9. 9.
    Luscombe, D.K., “Factors Influencing Plasma Drug Concentrations”, J. Int. Med. Res., S (Suppl.) pp. 82–97, 1977.Google Scholar
  10. 10.
    Murphy, H.B.M., “Ethnic Variations in Drug Response: Results of an International Survey,” Trans. Cult. Psych. Res., 6:5–23, 1969.CrossRefGoogle Scholar
  11. 11.
    Weinshilboun, R.M., “Research Review: Biochemical Genetics of Catecholamines in Humans,” Mayo Clin. Proc. 58: pp.319–330 1983.Google Scholar
  12. 12.
    Reilly, D.K., Rivera — Calimlim, L., “Racial Difference in Catechol-0-Methyl-Transferase Activity. A comparison of Filipinos with Caucasians in the U.S.A. Clin. Pharmacol. Ther. 25: pp. 244, 1979.Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Madeline Gomez
    • 1
  • Evaristo Gomez
    • 2
  1. 1.Ravenswood Hospital C.M.H.C.Univ. of IL.ChicagoUSA
  2. 2.Attending Physician Ravenswood and Barclay HospitalsU. of I.ChicagoUSA

Personalised recommendations